알레르기성 비염 시장 규모, 점유율, 동향 분석 보고서 : 질환 유형별, 약물 계열별, 투여 경로별, 처방 유형별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Allergic Rhinitis Market Summary

The global allergic rhinitis market size was valued at USD 15.9 billion in 2025 and is projected to grow from USD 16.5 billion in 2026 to USD 22.4 billion by 2033, at a CAGR of 4.5% from 2026 to 2033. The market in North America dominated with a revenue share of 41.2% in 2025. The market is supported by the increasing prevalence of allergic diseases, rising exposure to environmental allergens, air pollution, changing climatic conditions, and rapid urbanization across several regions.

Greater awareness of allergy symptoms, improved access to diagnostic services, and expanding healthcare infrastructure have contributed to higher diagnosis and treatment rates. The market comprises prescription and over-the-counter therapies, including antihistamines, intranasal corticosteroids, decongestants, and allergen immunotherapy, providing multiple treatment options based on disease severity and patient needs. Continuous investment in formulation improvements, combination therapies, and convenient drug delivery systems has strengthened product competitiveness and treatment adherence. Demand is also supported by expanding retail and online pharmacy networks, increasing healthcare expenditure in emerging economies, and a greater focus on long-term disease management. Ongoing clinical research, product innovation, and broader access to allergy care continue to support portfolio expansion, resulting in a competitive market with sustained opportunities for pharmaceutical manufacturers and healthcare providers.

Global Allergic Rhinitis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global allergic rhinitis market report based on disease type, drug class, route of administration, prescription type, distribution channel, and region:

• Disease Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Seasonal Allergic Rhinitis (SAR)
• Perennial Allergic Rhinitis (PAR)
• Occupational Allergic Rhinitis (OAR)
• Intermittent Allergic Rhinitis
• Persistent Allergic Rhinitis
• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Intranasal Corticosteroids
• Oral Antihistamines
• Intranasal Antihistamines
• Leukotriene Receptor Antagonists
• Nasal Decongestants
• Mast Cell Stabilizers
• Anticholinergics
• Allergen Immunotherapy
• Combination Therapies
• Others
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Intranasal
• Oral
• Subcutaneous
• Sublingual
• Others
• Prescription Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Prescription (Rx)
• Over the Counter (OTC)
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Prescription Type
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Allergic Rhinitis Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Allergic Rhinitis Market: Disease Type Business Analysis

• 4.1. Disease Type Market Share, 2025 & 2033
• 4.2. Disease Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
• 4.4. Seasonal Allergic Rhinitis (SAR)
  • 4.4.1. Seasonal Allergic Rhinitis (SAR) Market, 2021 - 2033 (USD Billion)
• 4.5. Perennial Allergic Rhinitis (PAR)
  • 4.5.1. Perennial Allergic Rhinitis (PAR) Market, 2021 - 2033 (USD Billion)
• 4.6. Occupational Allergic Rhinitis (OAR)
  • 4.6.1. Occupational Allergic Rhinitis (OAR) Market, 2021 - 2033 (USD Billion)
• 4.7. Intermittent Allergic Rhinitis
  • 4.7.1. Intermittent Allergic Rhinitis Market, 2021 - 2033 (USD Billion)
• 4.8. Persistent Allergic Rhinitis
  • 4.8.1. Persistent Allergic Rhinitis Market, 2021 - 2033 (USD Billion)

Chapter 5. Allergic Rhinitis Market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2025 & 2033
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
• 5.4. Intranasal Corticosteroids
  • 5.4.1. Intranasal Corticosteroids Market, 2021 - 2033 (USD Billion)
• 5.5. Oral Antihistamines
  • 5.5.1. Oral Antihistamines Market, 2021 - 2033 (USD Billion)
• 5.6. Intranasal Antihistamines
  • 5.6.1. Intranasal Antihistamines Market, 2021 - 2033 (USD Billion)
• 5.7. Leukotriene Receptor Antagonists
  • 5.7.1. Leukotriene Receptor Antagonists Market, 2021 - 2033 (USD Billion)
• 5.8. Nasal Decongestants
  • 5.8.1. Nasal Decongestants Market, 2021 - 2033 (USD Billion)
• 5.9. Mast Cell Stabilizers
  • 5.9.1. Mast Cell Stabilizers Market, 2021 - 2033 (USD Billion)
• 5.10. Anticholinergics
  • 5.10.1. Anticholinergics Market, 2021 - 2033 (USD Billion)
• 5.11. Allergen Immunotherapy
  • 5.11.1. Allergen Immunotherapy Market, 2021 - 2033 (USD Billion)
• 5.12. Combination Therapies
  • 5.12.1. Combination Therapies Market, 2021 - 2033 (USD Billion)
• 5.13. Others
  • 5.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Allergic Rhinitis Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
• 6.4. Intranasal
  • 6.4.1. Intranasal Market, 2021 - 2033 (USD Billion)
• 6.5. Oral
  • 6.5.1. Oral Market, 2021 - 2033 (USD Billion)
• 6.6. Subcutaneous
  • 6.6.1. Subcutaneous Market, 2021 - 2033 (USD Billion)
• 6.7. Sublingual
  • 6.7.1. Sublingual Market, 2021 - 2033 (USD Billion)
• 6.8. Others
  • 6.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Allergic Rhinitis Market: Prescription Type Business Analysis

• 7.1. Prescription Type Market Share, 2025 & 2033
• 7.2. Prescription Type Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Billion)
• 7.4. Prescription (Rx)
  • 7.4.1. Prescription (Rx) Market, 2021 - 2033 (USD Billion)
• 7.5. Over the Counter (OTC)
  • 7.5.1. Over the Counter (OTC) Market, 2021 - 2033 (USD Billion)

Chapter 8. Allergic Rhinitis Market: Distribution Channel Business Analysis

• 8.1. Distribution Channel Market Share, 2025 & 2033
• 8.2. Distribution Channel Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 9. Allergic Rhinitis Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Allergic Rhinitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. Canada Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.5. Europe
  • 9.5.1. Europe Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. UK Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.7. Latin America
  • 9.7.1. Latin America Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Brazil Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. Argentina Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Allergic Rhinitis Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Sanofi
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Bayer AG
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Haleon plc
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Kenvue Inc.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Glenmark Pharmaceuticals Ltd.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. ALK-Abello A/S
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Stallergenes Greer
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Viatris Inc.
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Teva Pharmaceutical Industries Ltd.
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Merck & Co., Inc.
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives